University of British Columbia
Uncovering and exploiting biological vulnerabilities in synovial sarcoma
Abstract
dc:descriptionSynovial Sarcoma (SS) is an aggressive soft tissue cancer driven by the SS18::SSX fusion oncoprotein. SS18::SSX activates developmental programs which impede differentiation and enhance cell proliferation. Current treatments rely on surgical resection with (neo)adjuvant radiation and/or cytotoxic chemotherapy, with no effective systemic therapy available for patients with disseminated disease. First line treatments, doxorubicin and ifosfamide, elicit only temporary responses while conferring high toxicities. Second line therapies, pazopanib and trabectedin, yield partial responses in only 10-20% of patients. Despite multimodal treatment, recurrences are common, with 5-year survival rates of ~60% overall and <10% with disseminated disease. Thus, the discovery of more effective drugs targeting SS would greatly improve patient outcomes. To identify clinically actionable vulnerabilities in SS, we performed a high-throughput in vitro screen of 3,300 FDA-approved compounds. We identified 373 drugs more cytotoxic to SS cells than doxorubicin while exhibiting reduced toxicity to non-transformed fibroblasts. Sequential validation highlighted six drugs demonstrating efficacy across multiple SS cell lines at nanomolar concentrations. In parallel, interrogation of DepMap dependency data revealed three additional compounds targeting critical genetic dependencies in SS. The aforementioned compounds were tested in comparison to current therapies in a genetically engineered, immunocompetent mouse model of SS driven by conditional expression of human SS18::SSX2. The top agent, milciclib (CDK2/4 inhibitor) produced larger tumor regression with minimal toxicity compared to doxorubicin. Other agents, cladribine and sitravatinib, showed efficacy comparable to doxorubicin, with fewer adverse effects. Mechanistically, SS18::SSX drives oncogenesis largely through epigenetic reprogramming and activation of Wnt/β-catenin, Notch, and receptor tyrosine kinase pathways. While inhibition of individual pathways has yielded inconsistent results, these signals converge on G1/S cell-cycle control switches, including CDK2/4. Transcriptomic, histologic, and cell-cycle analyses demonstrated that milciclib suppresses SS growth by inhibiting CDK2/4, thereby preventing retinoblastoma protein phosphorylation and cell cycle progression. Notably, siRNA-mediated CDK2/4 knockdown phenocopied these effects, supporting this proposed mechanism of drug activity. Collectively, these findings establish our genetically engineered SS mouse model as a robust and efficient platform for preclinical drug testing, and provide the strongest in vivo evidence to date that CDK2/4 inhibition represents a potentially highly effective strategy for the treatment of SS.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Medicine / Doctor of Philosophy - MD/PhD
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Interdisciplinary Oncology
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Wang, Amy Xueqi
- Contributors dc:contributor
-
- Underhill, T M
- Nielsen, Torsten
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/95487